AEON Biopharma Statistics
Total Valuation
AEON Biopharma has a market cap or net worth of $23.58 million. The enterprise value is $39.55 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AEON Biopharma has 39.97 million shares outstanding. The number of shares has decreased by -66.29% in one year.
| Current Share Class | 39.97M |
| Shares Outstanding | 39.97M |
| Shares Change (YoY) | -66.29% |
| Shares Change (QoQ) | +1.73% |
| Owned by Insiders (%) | 6.06% |
| Owned by Institutions (%) | 6.60% |
| Float | 14.73M |
Valuation Ratios
The trailing PE ratio is 1.71.
| PE Ratio | 1.71 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 2.89 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.22
| Current Ratio | 0.22 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -194.80% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $1.37M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.16% in the last 52 weeks. The beta is 0.20, so AEON Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -90.16% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 2.40 |
| Relative Strength Index (RSI) | 43.04 |
| Average Volume (20 Days) | 307,676 |
Short Selling Information
The latest short interest is 164,257, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 164,257 |
| Short Previous Month | 153,113 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 1.12% |
| Short Ratio (days to cover) | 1.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.70M |
| Pretax Income | -323.95M |
| Net Income | 13.68M |
| EBITDA | -33.60M |
| EBIT | -33.70M |
| Earnings Per Share (EPS) | $0.34 |
Full Income StatementBalance Sheet
The company has $537,000 in cash and $16.50 million in debt, giving a net cash position of -$15.97 million or -$0.40 per share.
| Cash & Cash Equivalents | 537,000 |
| Total Debt | 16.50M |
| Net Cash | -15.97M |
| Net Cash Per Share | -$0.40 |
| Equity (Book Value) | -32.09M |
| Book Value Per Share | -0.81 |
| Working Capital | -8.36M |
Full Balance SheetCash Flow
| Operating Cash Flow | -30.69M |
| Capital Expenditures | n/a |
| Free Cash Flow | -30.69M |
| FCF Per Share | -$0.77 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |